31 December 2021

Crescendo Biologics announces publication of data for CB213, a PD-1xLAG-3 multi-specific Humabody®, in the British Journal of Cancer

View PDF

16 December 2021

Crescendo to attend upcoming investor conferences

View PDF

26 November 2021

Crescendo Biologics wins “Best Established Biotech Company” at the 2021 OBN Awards

View PDF

21 October 2021

Crescendo Biologics announces that Zai Lab has achieved proof-of-concept for ZL-1102 (Humabody®, CB001) in a Phase 1b clinical trial in psoriasis patients View PDF

20 October 2021

Crescendo Biologics announces prestigious new collaboration with The Institute of Cancer Research, London View PDF

16 September 2021

Crescendo to participate in upcoming investor conferences View PDF

07 July 2021

Crescendo to participate in upcoming investor conferences 

View PDF

01 June 2021

Crescendo to participate in upcoming investor conferences View PDF

20 May 2021

Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours View PDF

10 May 2021

Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer View PDF

27 April 2021

Crescendo to participate in upcoming investor conferences View PDF

19 April 2021

Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology View PDF

16 April 2021

New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours View PDF